Juniper Pharma (JNP) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Juniper Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 4, 2015 7:00 AM EDTBOSTON, Aug. 4, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") a women's health specialty pharmaceutical company, today announced financial results for the three months ended June 30, 2015. Highlights include:
Patient enrollment is underway and on track in the Phase 2 clinical study of COL-1077 10% lidocaine bioadhesive gel; Total revenues increased 53% year-over-year to $10.2 million, driven by an 89% increase in product revenues and 29% growth in service revenues; $16.1 million in cash and equivalents at... More